Almirall and IRB Barcelona (the Institute for Research in Biomedicine), will conduct research using molecular glue degraders, a new approach to the skin diseases under scrutiny. The use of ...

Almirall, S.A., a biopharmaceutical company, engages in the purchase, manufacture, storage, and sale of skin-health medicines in Europe, the Middle East, the United ...

No significant news for in the past two years. Key Stock Data P/E Ratio (TTM) The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing ...

This medication is used to treat migraines. Almotriptan (trade name Axert and others) is a triptan drug discovered and developed by Almirall for the treatment of heavy migraine headache.

A study led by researchers from the Dementia Neurobiology Group at the Sant Pau Research Institute, published today in the journal Nature Medicine, has identified that almost all individuals with two ...

The IPC's definition and diagnostic criteria for GPP minimized the complexity of clinical considerations to speed treatment of this potentially life-threatening condition.

Already embraced by leading names in the beauty, skincare, and pharmaceutical industries, Haut.AI’s platform is utilized by global brands such as Beiersdorf, Ulta Beauty, the largest beauty retailer ...

These volunteers were recruited by the IDIBAPS Primary healthcare transversal research group, led by Antoni Sisó Almirall. The experts meticulously examined two parameters among the participants: the ...

He will take over from interim CEO Sergio Marullo di Condojanni. Later in the month, Almirall announced that Mercedes Diaz would be promoted to VP of corporate strategy. Diaz has been with ...

At Almirall, a global pharmaceutical company focused in medical dermatology, we firmly believe in partnerships to share knowledge, science and efforts, and to build synergies that accelerate the R ...

Additionally, with the global licensing partnership with Almirall announced in March, the company has begun the development of ZKN-013 for the treatment of Recessive Dystrophic Epidermolysis Bullosa ...